U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07343323) titled 'A First-in-Human Study of KINE-101 in Healthy Volunteers' on Dec. 10, 2025.
Brief Summary: This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study that evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous (IV) and subcutaneous (SC) formulations of KINE-101 in healthy volunteers at a single study center. Five cohorts of eight subjects each (six receiving KINE-101 and two receiving placebo) are admitted on Day -1, receive a single dose of investigational medicinal product (IMP) on Day 1, and remain in-house until Day 3, followed by outpatient vis...